{"id":3839,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/cimetidine-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"cimetidine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/cimetidine-txt\/","title":{"rendered":"Cimetidine.txt"},"content":{"rendered":"

Cimetidine<\/h1>\n

CLINICAL USE <\/H3>
\nH2 antagonist:Conditions associated with hyperacidity Refractory uraemic pruritus (unlicensed use)

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: duodenal and gastric ulceration treatment: 800 mg at night, or 400 mg twice daily; rarely, up to 1.6 g dailyProphylaxis: 400 mg at night or 400 mg twice dailyProphylaxis of stress ulceration: 200\u2013 400 mg every 4\u20136 hoursReflux oesophagitis: 400 mg every 6 hours IM\/IV: 200 mg every 4\u20136 hours, maximum 2.4 g dailyIV Infusion: 200\u2013400 mg every 4\u20136 hours intermittent or 50\u2013100 mg\/hour continuous, maximum 2.4 g dailyZollinger-Ellison syndrome: 400 mg every 4\u20136 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :252.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :20<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50\u201375<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1\u20131.3<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/5

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : 50% of normal dose
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 50% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. 300 mg every 8 hours1

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAlpha-blockers: effects of tolazoline antagonisedAnti-arrhythmics: increased concentration of amiodarone, flecainide, lidocaine, procainamide and propafenoneAnticoagulants: enhanced effect of coumarinsAnti-epileptics: metabolism of carbamazepine, phenytoin and valproate inhibited. Antifungals: absorption of itraconazole and ketoconazole reduced; posaconazole concentration reduced; terbinafine concentration increasedAntimalarials: avoid concomitant use with artemether\/lumefantrine; metabolism of chloroquine, hydroxychloroquine and quinine inhibitedAntipsychotics: possibly enhanced effect of antipsychotics, chlorpromazine and clozapine; increased risk of ventricular arrhythmias with sertindole \u2013 avoid concomitant useCiclosporin: possibly increased ciclosporin levelsCilostazol: possibly increased cilostazol concentration \u2013 avoid concomitant useCytotoxics: concentration of epirubicin and fluorouracil increased.156 CiMETidinEErgot alkaloids: increased risk of ergotism \u2013 avoid concomitant useTheophylline: metabolism of theophylline inhibited

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IM, IV

    Rate of Administration <\/H4>IV Infusion: 400 mg in 100 mL sodium chloride 0.9% or glucose 5% over 30\u201360 minutesIV bolus: 200 mg over at least 5 minutes. Dilute larger doses to 10 mL and give over at least 10 minutesContinuous IV Infusion: 50\u2013100 mg\/hour

    Comments<\/H4>Avoid bolus if possible

    OTHER INFORMATION <\/H4>Inhibits tubular secretion of creatinine Uraemic patients susceptible to mental confusion
    \n","protected":false},"excerpt":{"rendered":"

    Cimetidine CLINICAL USE H2 antagonist:Conditions associated with hyperacidity Refractory uraemic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3839","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3839"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3839\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}